反式-4-羟基-4-甲基-2-戊烯酸 | 10208-72-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 反式-4-羟基-4-甲基-2-戊烯酸
• 英文名称: trans-4-hydroxy-4-methyl-2-pentenoic acid
• 英文别名: (E)-4-hydroxy-4-methylpent-2-enoic acid；4-hydroxy-4-methyl-pent-2t-enoic acid；4-Hydroxy-4-methyl-pent-2t-ensaeure；γ-Oxy-γ.γ-dimethyl-crotonsaeure；γ-Oxy-γ-methyl-α-butylen-α-carbonsaeure；2-Methyl-penten-(3)-ol-(2)-saeure-(5)；Terelactonsaeure
• CAS: 10208-72-7
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: PDFAAQLHHBQRPO-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  反式-4-羟基-4-甲基-2-戊烯酸 、 4-hydroxytiglic acid 生成 (E)-4-羟基-4-甲基戊-2-烯-1-酸甲酯
  参考文献：
  名称：

  RUSTAIYAN, A.;BAMONIERI, A.;RAFFATRAD, M.;JAKUPOVIC, J.;BOHLMANN, F., PHYTOCHEMISTRY, 26,(1987) N 8, 2307-2310

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基戊-2-烯酸乙酯 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 AgOH 作用下， 以 四氯化碳 、 乙醇 为溶剂， 反应 5.0h， 生成 反式-4-羟基-4-甲基-2-戊烯酸
  参考文献：
  名称：

  Agarwal, S. G.; Thappa, R. K.; Dhar, K. L., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1981, vol. 20, # 2, p. 164 - 165

  摘要：

  DOI：

文献信息

• [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PFIZER

  公开号：WO2014068527A1

  公开（公告）日：2014-05-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

  本文披露了一种与Bruton's酪氨酸激酶（BTK）形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症，包括淋巴瘤，以及炎症性疾病或症状的方法。 (化学式I)
• The photochemistry of <i>trans</i>-isohumulone, a bitter flavouring component of beer
  作者：Alan C Weedon、John S Morrison

  DOI：10.1139/v08-072

  日期：2008.8.1

  Methanolic solutions of trans-isohumulone (2), a major bitter flavouring component in beer, were irradiated with UV light of 313 nm wavelength and yielded four primary products containing an enolized cyclic β-triketone moiety: cis-isohumulone (3), humulone (1), dehydro-isohumulone (7), and dehydro-humulinic acid (5). The last of these products results from loss of the 4-methyl-3-pentenoyl side chain of trans-isohumulone. Nine volatile products derived from this side chain were identified and quantitated. The identifications of all photoproducts were confirmed by independent preparation of authentic samples. No evidence of either intramolecular or intermolecular 2+2 cyclo-addition was observed. This work clarifies previous contradictory reports of the products of isohumulone photolysis and provides an example of unexpected photochemistry of an alkenyl-substituted enolized cyclic β-triketone.Key words: trans-isohumulone, photo-degradation, cyclic β-triketone.

  反式-异胡麻酮（2）是啤酒中的一种主要苦味香料成分，其甲醇溶液经波长为 313 纳米的紫外线照射后，产生了四种含有烯醇化环β-三酮分子的初级产品：顺式-异胡麻酮（3）、胡麻酮（1）、脱氢-异胡麻酮（7）和脱氢-胡麻酸（5）。最后一种产品是反式-异胡柚酮的 4-甲基-3-戊烯酰侧链脱落后产生的。从该侧链衍生出的九种挥发性产物已被鉴定和定量。所有光反应产物的鉴定结果都已通过独立制备真实样品得到证实。没有观察到分子内或分子间 2+2 环加成的证据。这项研究澄清了之前关于异胡麻酮光解产物的相互矛盾的报道，并提供了一个烯基取代烯醇化环β-三酮的意想不到的光化学实例。
• Regioselectivity in the ene reaction of singlet oxygen with alkenes bearing an electron withdrawing group at β- position
  作者：Manolis Stratakis、Michael Orfanopoulos

  DOI：10.1016/s0040-4039(96)02469-0

  日期：1997.2

  Electronic repulsions between a perepoxide intermediate and the allylic functionality in the product forming transition state, direct the regioselectivity in the photooxygenation of trisubstituted alkenes bearing an electron withdrawing group at β- position.

  在形成过渡态的产物中，过氧化物中间体与烯丙基官能团之间的电子排斥作用指导在β-位置带有吸电子基团的三取代烯烃的光氧化中的区域选择性。
• Bruton's Tyrosine Kinase Inhibitors
  申请人：PFIZER INC.

  公开号：US20150291554A1

  公开（公告）日：2015-10-15

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。披露了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。披露了使用BTK抑制剂的方法，单独或与其他治疗剂一起，用于治疗自身免疫性疾病或状况、异种免疫性疾病或状况、包括淋巴瘤的癌症和炎症性疾病或状况。
• Bruton's tyrosine kinase inhibitors
  申请人：Pfizer Inc.

  公开号：US10266513B2

  公开（公告）日：2019-04-23

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文公开了与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。还公开了制备这些化合物的方法。还公开了包括这些化合物的药物组合物。本发明公开了使用BTK抑制剂的方法，这些抑制剂可单独使用，也可与其它治疗剂联合使用，用于治疗自身免疫性疾病或病症、异种免疫性疾病或病症、癌症（包括淋巴瘤）以及炎症性疾病或病症。